MOUNTAIN VIEW, Calif., Feb 23 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following events in March:
Advertisement
A live webcast of the events will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.
Advertisement
About MAP Pharmaceuticals
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.
RBC Capital Markets 2010 Healthcare Conference Panel: Specialty Pharma - Adapting a Changing Business Model Tuesday, March 2, at 3:35 p.m. ET in New York City Cowen and Company 30th Annual Healthcare Conference Wednesday, March 10, at 8:00 a.m. ET in Boston
SOURCE MAP Pharmaceuticals, Inc.
